42.31
price down icon1.33%   -1.335
 
loading
Schlusskurs vom Vortag:
$43.65
Offen:
$43.86
24-Stunden-Volumen:
70,336
Relative Volume:
0.06
Marktkapitalisierung:
$5.20B
Einnahmen:
$10.60M
Nettoeinkommen (Verlust:
$-252.45M
KGV:
-13.65
EPS:
-3.1
Netto-Cashflow:
$-158.91M
1W Leistung:
-13.81%
1M Leistung:
-7.79%
6M Leistung:
+45.95%
1J Leistung:
+634.98%
1-Tages-Spanne:
Value
$42.30
$44.68
1-Wochen-Bereich:
Value
$39.50
$50.32
52-Wochen-Spanne:
Value
$5.93
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Firmenname
Avidity Biosciences Inc
Name
Telefon
858-401-7900
Name
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
253
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
RNA's Discussions on Twitter

Vergleichen Sie RNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
RNA 42.31 5.20B 10.60M -252.45M -158.91M -3.10
VRTX 445.46 115.74B 10.63B -479.80M -1.35B 13.33
REGN 736.17 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 585.04 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 247.45 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.20 24.49B 3.30B -501.07M 1.03B 11.54

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-24 Eingeleitet Goldman Buy
2024-08-28 Eingeleitet Barclays Overweight
2024-05-03 Eingeleitet BofA Securities Buy
2024-03-14 Eingeleitet Cantor Fitzgerald Overweight
2023-05-22 Hochstufung Evercore ISI In-line → Outperform
2023-03-31 Herabstufung Evercore ISI Outperform → In-line
2022-07-20 Eingeleitet Chardan Capital Markets Buy
2022-07-12 Eingeleitet Raymond James Strong Buy
2021-09-07 Eingeleitet Evercore ISI Outperform
2021-06-17 Eingeleitet Needham Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-07-07 Eingeleitet Cowen Outperform
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-07-07 Eingeleitet SVB Leerink Outperform
2020-07-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten

pulisher
Nov 20, 2024

Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Mutual of America Capital Management LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Avidity Biosciences unveils new cardiology development candidates - BioWorld Online

Nov 14, 2024
pulisher
Nov 14, 2024

RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - Yahoo! Voices

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire

Nov 13, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire

Nov 12, 2024
pulisher
Nov 09, 2024

Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance

Nov 09, 2024
pulisher
Nov 09, 2024

431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Bio's DMD Drug Shows 25% Dystrophin Boost; Reports $1.6B Cash Position | RNA Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5%What's Next? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com

Nov 04, 2024
pulisher
Nov 02, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused o - GuruFocus.com

Nov 02, 2024
pulisher
Oct 31, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 – Company AnnouncementFT.com - Financial Times

Oct 31, 2024
pulisher
Oct 31, 2024

Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com

Oct 30, 2024

Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Avidity Biosciences Inc-Aktie (RNA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
McCarthy Teresa
Chief Human Resources Officer
Nov 18 '24
Sale
41.14
25,000
1,028,520
94,018
LEVIN ARTHUR A
Director
Nov 19 '24
Option Exercise
1.24
3,323
4,121
18,153
LEVIN ARTHUR A
Director
Nov 19 '24
Sale
42.12
3,323
139,973
14,830
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Option Exercise
8.43
79,057
666,064
159,275
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Sale
45.56
106,319
4,843,979
94,093
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):